Academic Journal
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
| العنوان: | The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD) |
|---|---|
| المؤلفون: | TERRAGNA, CAROLINA, REMONDINI, DANIEL, MARTELLO, MARINA, ZAMAGNI, ELENA, PANTANI, LUCIA, Patriarca, Francesca, PEZZI, ANNALISA, LEVI, GIUSEPPE, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, TACCHETTI, PAOLA, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, SANTACROCE, BARBARA, BORSI, ENRICA, BRIOLI, ANNAMARIA, MARZOCCHI, GIULIA, CASTELLANI, GASTONE, MARTINELLI, GIOVANNI, Palumbo, Antonio, CAVO, MICHELE |
| المساهمون: | Terragna, Carolina, Remondini, Daniel, Martello, Marina, Zamagni, Elena, Pantani, Lucia, Patriarca, Francesca, Pezzi, Annalisa, Levi, Giuseppe, Offidani, Massimo, Proserpio, Ilaria, De Sabbata, Giovanni, Tacchetti, Paola, Cangialosi, Clotilde, Ciambelli, Fabrizio, Viganò, Clara Virginia, Dico, Flores Angela, Santacroce, Barbara, Borsi, Enrica, Brioli, Annamaria, Marzocchi, Giulia, Castellani, Gastone, Martinelli, Giovanni, Palumbo, Antonio, Cavo, Michele |
| سنة النشر: | 2016 |
| المجموعة: | IRIS Università degli Studi di Bologna (CRIS - Current Research Information System) |
| مصطلحات موضوعية: | SNP, VTD, complete response, gene expression profile, multiple myeloma |
| الوصف: | The prime focus of the current therapeutic strategy for Multiple Myeloma (MM) is to obtain an early and deep tumour burden reduction, up to the level of complete response (CR). To date, no description of the characteristics of the plasma cells (PC) prone to achieve CR has been reported. This study aimed at the molecular characterization of PC obtained at baseline from MM patients in CR after bortezomib-thalidomide-dexamethasone (VTD) first line therapy.One hundred and eighteen MM primary tumours obtained from homogeneously treated patients were profiled both for gene expression and for single nucleotide polymorphism genotype. Genomic results were used to obtain a predictor of sensitivity to VTD induction therapy, as well as to describe both the transcription and the genomic profile of PC derived from MM with subsequent optimal response to primary induction therapy.By analysing the gene profiles of CR patients, we identified a 5-gene signature predicting CR with an overall median accuracy of 75% (range: 72%-85%). In addition, we highlighted the differential expression of a series of genes, whose deregulation might explain patients' sensitivity to VTD therapy. We also showed that a small copy number loss, covering 606Kb on chromosome 1p22.1 was the most significantly associated with CR patients. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | ELETTRONICO |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/26575327; info:eu-repo/semantics/altIdentifier/wos/WOS:000375672900006; volume:7; issue:9; firstpage:9666; lastpage:9679; numberofpages:14; journal:ONCOTARGET; http://hdl.handle.net/11585/529113; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-84961572031; http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5718&pubmed-linkout=1 |
| DOI: | 10.18632/oncotarget.5718 |
| الاتاحة: | http://hdl.handle.net/11585/529113 https://doi.org/10.18632/oncotarget.5718 http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5718&pubmed-linkout=1 |
| رقم الانضمام: | edsbas.6BD22B39 |
| قاعدة البيانات: | BASE |
| DOI: | 10.18632/oncotarget.5718 |
|---|